EU
#JunckerPlan ondersteun chroniese siektevoorkoming in #Finland
Die Beleggingsplan vir Europa, of Juncker Plan, is backing a €20 million European Investment Bank (EIB) loan to Finnish company Nightingale Health. The company will use the financing to further develop its blood analysis technology, which facilitates the detection and prevention of chronic diseases.
Jobs, Growth, Investment and Competitiveness Vice President Jyrki Katainen, who attended the signature event in Helsinki, said: "Europe invests heavily in education and science as we believe that putting a strategic effort into these areas can reap huge benefits. This commitment has resulted in Europe's position today as a world leader in cutting edge medical research. We are delighted that the Investment Plan for Europe is fostering the development of Nightingale's technology which has the potential to add significant value to European healthcare."
Nightingale's innovative blood analysis technology can detect early signs of chronic diseases, improving for example the assessment of a person's future risk of developing heart disease or type 2 diabetes. A press release is available na hierdie skakel. As of December 2018, the European Fund for Strategic Investments (EFSI), at the heart of the Juncker Plan, had already mobilized €371.2 billion of additional investments, including €7.8bn in Finland.
Deel hierdie artikel:
-
Frankryk5 dae gelede
Frankryk aanvaar nuwe anti-kultuswet teen Senaat se opposisie
-
Konferensies5 dae gelede
Nasionale Konserwatiewes belowe om voort te gaan met Brussel-geleentheid
-
Konferensies2 dae gelede
NatCon se aan-af-konferensie is deur die Brusselse polisie gestaak
-
massa toesig3 dae gelede
Lek: EU-ministers van binnelandse sake wil hulself vrystel van kletsbeheer grootmaat skandering van private boodskappe